Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1

ash.confex.com

Oral and Poster Abstracts Oral 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Innovative induction regimens in AML: data from real life and clinical trials Acute Myeloid Malignancies, AML, Clinical Research, Clinically Relevant, Diseases, Real World Evidence, Therapies, Myeloid...

  • A retrospective review of 332 patients with treatment related MDS and AML looked at outcomes of VEN based therapy. In the VIALE-A study of AZA-VEN vs AZA alone in older/frail patients with AML 36% of patients had t-AML, although subgroup analysis indicated they had similar benefit, and had better median survival then the denovo group the numbers were small. In this present study, 19.6% of the patients with t-mds/aml received VEN based therapy. Patients with higher blast count and t-AML were more likely to receive VEN. Most patients had VEN paired with HMA. Median OS was 6.5 months. VEN as first line of therapy and when in combination with HMA was associated with better responses and outcomes. This study suggests shorter responses and higher rate of progression than I would of expected based on VIALE-A.